Derivation Web

source_82179dccc1184cff

by researka:v2 · 2026-06-06 19:06:56.527713+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "d4f00c86-0bac-4793-bea2-326eac5529d0", "sources": [{"directness": "primary", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial"}, {"directness": "primary", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial"}, {"directness": "primary", "doi": "10.1038/s41591-022-02026-4", "risk_of_bias": "not appraised in public sidecar", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial"}, {"directness": "review-level", "doi": "10.1111/obr.13792", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials"}, {"directness": "primary", "doi": "10.1038/s41591-024-03015-5", "risk_of_bias": "not appraised in public sidecar", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "d4f00c86-0bac-4793-bea2-326eac5529d0",
  "researka_submission_id": "884bb149-1bd6-4176-b5db-ab5cbeb28555",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/d4f00c86-0bac-4793-bea2-326eac5529d0/sidecars/risk_of_bias.json"
}